Hypertonic Saline and Mucociliary Clearance in Children

This study has been completed.
Sponsor:
Collaborator:
Cystic Fibrosis Foundation
Information provided by:
Johns Hopkins University
ClinicalTrials.gov Identifier:
NCT01293084
First received: February 9, 2011
Last updated: NA
Last verified: January 2011
History: No changes posted
  Purpose

Previously, the investigators and others have shown that mucociliary clearance (MCC) is defective in patients with cystic fibrosis (CF) and it is now thought that alterations in airway mucus rheology figure prominently in the impairment. Mucociliary clearance works by trapping toxic particles, bacteria and viruses in the lung mucus and then quickly removing the mucus out of the lungs. Defects in MCC typically lead to the accumulation of mucus in the airways, and this in turn is associated with acute infections, chronic bacterial colonization and chronic inflammation. One treatment strategy that is gaining acceptance as an important therapy for improving MCC in adults with CF is the inhalation of the osmotic stimulus, hypertonic saline (HS). A number of studies have shown that acute inhalation of HS (7% saline) significantly improves MCC in adults with CF and results from a recent study indicate that two weeks of inhaling HS leads to a significant increase in MCC that is sustained for 8 hours post inhalation and is associated with significant improvements in FEV1, FVC and FEF25-75 values. Since MCC in patients with CF appears to be impaired by adulthood, any drug that disrupts or slows the impairment in childhood could prove enormously beneficial in the long-term prognosis of the disease. Nevertheless, no studies have been conducted to determine if HS treatment improves MCC in children with CF. This is most problematic for physicians who care for children with CF who have normal FEV1 and FVC values, since it is unclear if they should treat these children with HS or not. This research study is designed to begin to answer this question. The investigators hypothesize that acute inhalation of hypertonic saline (7%) will improve MCC in CF children with normal pulmonary function. Our hypothesis will be tested in a one-year clinical trial that will be randomized and placebo-controlled. Twelve children with CF who are 7-12 years old and have normal FEV1 and FVC values will participate. Our goal will be to compare MCC in these children on two study visits after acute inhalations of placebo (0.12% saline) or hypertonic saline (HS) (7% saline) aerosol. The investigators predict that MCC values after acute inhalation of 7% HS aerosol will be statistically significantly greater than after placebo inhalation.


Condition Intervention Phase
Cystic Fibrosis
Drug: 0.12% saline
Drug: 7% saline
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Crossover Assignment
Masking: Double Blind (Subject, Caregiver, Investigator)
Primary Purpose: Treatment
Official Title: Acute Inhalation of Hypertonic Saline Does Not Improve Mucociliary Clearance in All Children With Cystic Fibrosis

Resource links provided by NLM:


Further study details as provided by Johns Hopkins University:

Primary Outcome Measures:
  • Percent mucociliary clearance at 60 minutes [ Time Frame: 60 minutes ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Percent mucociliary clearance at 90 minutes [ Time Frame: 90 minutes ] [ Designated as safety issue: No ]

Enrollment: 12
Study Start Date: July 2007
Study Completion Date: June 2009
Primary Completion Date: June 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 7% saline
5 mL of 7% saline was inhaled once over a 20 minute period.
Drug: 7% saline
5mL 7% saline inhaled once over 20 minutes
Other Name: hypertonic saline
Placebo Comparator: 0.12% saline
5mL 0.12% saline inhaled once during 20 minutes
Drug: 0.12% saline
5mL of 0.12% saline inhaled once over 20 minutes

Detailed Description:

Several studies report that mucociliary clearance (MCC) is impaired in adults with CF. Because MCC is an important airway defense mechanism, drugs that slow impairment of MCC in children could prove beneficial in the long-term prognosis of the disease. A few studies have shown that inhalation of hypertonic saline (HS) significantly improves MCC in adults with CF and improvement is associated with increases in pulmonary function and decreases in pulmonary exacerbations. Nevertheless, no studies have examined if HS improves MCC in CF children. This is problematic for physicians who care for CF children with normal pulmonary function, since it is unclear if they should treat with HS or not. This study was designed to begin to answer this question. Twelve children with CF (7-12 yrs; 5 males) and normal pulmonary function (FEV1 and FVC > 90% of predicted values) participated in a screening visit and two study visits. On the screening visit, children underwent an induced sputum test. On the two study visits, they inhaled 0.12% saline (placebo), or HS, in a double-blind, randomized, cross-over study. Following inhalation of placebo or HS, patients inhaled the radioisotope 99mtechnetium and underwent sequential imaging of their lungs with a gamma camera for 90 min and approximately 24 hrs later. Mucociliary clearance was quantified at 60 min (MCC60), 90 min (MCC90) and 24 hrs (MCC24hrs) after inhalation of the radioisotope. Between the 60 min and 90 min measurements, children coughed 30 times.

  Eligibility

Ages Eligible for Study:   7 Years to 12 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Males and females
  • Age 7-12 years old
  • Diagnosis of cystic fibrosis by sweat chloride > 60 meq/L, or presence of two CFTR mutations known to cause CF
  • Routinely treated with the short-acting bronchodilator albuterol
  • FEV1 > 90% of predicted values

Exclusion Criteria:

  • FEV1 < 90% of predicted values
  • Routine use of hypertonic saline, mannitol, or amiloride
  • Allergic bronchopulmonary aspergillosis (ABPA)
  • Sputum colonization with Burkholderia cepacia or multiple antibiotic resistant organisms
  • Evidence of a pulmonary exacerbation within past two weeks
  • Treated with intravenous or oral antibiotics in the past two weeks for a pulmonary exacerbation
  • Presence of an acute respiratory illness characterized by:

    • Coughing above baseline values
    • Wheezing
    • Respiratory distress
    • Hemoptysis
  • Cannot perform the inhalation maneuvers that are required for drug inhalation or radioaerosol administration
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01293084

Sponsors and Collaborators
Johns Hopkins University
Cystic Fibrosis Foundation
Investigators
Principal Investigator: Beth L Laube, PhD Johns Hopkins University
  More Information

No publications provided by Johns Hopkins University

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Beth Laube/Professor, Johns Hopkins University School of Medicine
ClinicalTrials.gov Identifier: NCT01293084     History of Changes
Other Study ID Numbers: CFF Account #LAUBE06A0
Study First Received: February 9, 2011
Last Updated: February 9, 2011
Health Authority: United States: Food and Drug Administration

Keywords provided by Johns Hopkins University:
mucociliary clearance
children
cystic fibrosis
hypertonic saline

Additional relevant MeSH terms:
Cystic Fibrosis
Fibrosis
Pancreatic Diseases
Digestive System Diseases
Lung Diseases
Respiratory Tract Diseases
Genetic Diseases, Inborn
Infant, Newborn, Diseases
Pathologic Processes

ClinicalTrials.gov processed this record on September 16, 2014